— Proven Pharmaceutical Leader Brings Deep, Global Experience with Successful Product Launches, Commercialization and Strategic Planning — BRISBANE, Calif. --(BUSINESS WIRE)--Jan. 18, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially
BRISBANE, Calif. --(BUSINESS WIRE)--Jan. 4, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has entered into a $170 million loan agreement with an affiliate of KKR, a leading
BRISBANE, Calif. --(BUSINESS WIRE)--Jan. 2, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CEO Jayson Dallas , M.D., will present a company overview at the 37 th Annual J.P.
BRISBANE, Calif. --(BUSINESS WIRE)--Dec. 21, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has submitted a Biologics License Application (BLA) to the U.S.
— AR201 for Egg Allergy Phase 2 Initiation Planned for 2019 — — Michael Foods Is the Largest U.S. Processor of Value-Added Eggs — BRISBANE, Calif. --(BUSINESS WIRE)--Dec. 20, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially
BRISBANE, Calif. --(BUSINESS WIRE)--Dec. 19, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has initiated POSEIDON ( P eanut O ral Immunotherapy S tudy of E arly I
BRISBANE, Calif. --(BUSINESS WIRE)--Dec. 6, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Investor Symposium in New York City on December 12, 2018 .
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 28, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the closing of the $98 million equity investment by Nestlé Health Science.
— Treatment with AR101 significantly increased the amount of peanut protein tolerated and reduced the number and severity of reactions to peanut protein — — Aimmune conference call Monday, November 19 at 8:00 a.m. Eastern — BRISBANE, Calif. --(BUSINESS WIRE)--Nov.
— Nestlé Health Science to Invest $98 Million in Aimmune through the Purchase of 3.24 Million Shares of Aimmune Stock at $30.27 per Share — — Companies Extend Existing Strategic Collaboration Agreement Focused on Offering Innovative Food Allergy Therapies — — Nestlé Health Science CEO Greg Behar
